Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel and Celecoxib in Platinum-Resistant Ovarian Cancer
NCT00084448Phase 2Terminated
- Sponsor
- GOG Foundation
- Start
- Apr 2004
- Primary completion
- May 2005
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of celecoxib in ovarian epithelial cancer and primary peritoneal cancer (PPC), sponsored by GOG Foundation. Primary endpoints: Antitumor Activity and Toxicity. Started Apr 2004; status: terminated.
02
Drugs
celecoxib
03
Conditions
ovarian epithelial cancerprimary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NCT00084448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00084448.